Ruxience

Ruxience is a biosimilar drug developed by Pfizer for the treatment of certain types of cancer and autoimmune diseases. It is a biosimilar to the drug Rituximab, which is marketed under the brand names Rituxan and MabThera.

Overview

Ruxience is a monoclonal antibody that targets the CD20 protein found on the surface of B cells. By binding to this protein, Ruxience helps to destroy these cells, which can be beneficial in conditions where B cells are contributing to disease progression.

Indications

Ruxience is approved for use in several conditions, including:

• Non-Hodgkin's lymphoma
• Chronic lymphocytic leukemia
• Rheumatoid arthritis
• Granulomatosis with polyangiitis and Microscopic polyangiitis

Side Effects

Like all medications, Ruxience can cause side effects. The most common side effects include:

• Infection
• Infusion reactions
• Fatigue
• Nausea

See Also

• Biosimilar
• Monoclonal antibody
• Rituximab

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian